Journal
CANCER LETTERS
Volume 497, Issue -, Pages 100-111Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.10.016
Keywords
TNBC; Therapeutic resistance; DNA repair; Tumor microenvironment; Clinical trial; Targeted drug; Immunotherapy
Categories
Funding
- St George Cancer Care Centre Research Trust Fund
- Prostate and Breast Cancer Foundation
- China Scholarship Council
- UNSW Sydney
Ask authors/readers for more resources
TNBC shows higher response rate to systemic therapy but poorer tumor differentiation, with higher tendency to metastasis and recurrence. Relapsed and metastatic TNBCs progress more rapidly, demonstrating strong resistance to chemotherapy and radiotherapy.
Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available